Antares Pharma, Inc. provided revenue guidance for the year 2022. For the year, the company expects revenue to be range of $200 to $220 million, which does not include any unapproved products and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Excluding 2021 OTREXUP® proprietary revenue, the guidance range represents a 18% to 30% year-over-year growth rate.
Antares Pharma, Inc.
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-5.00% | 18TCr | |
+0.28% | 11TCr | |
-5.55% | 6.78TCr | |
+2.91% | 5.19TCr | |
+7.11% | 4.32TCr | |
+6.07% | 4.11TCr | |
+23.37% | 3.21TCr | |
+15.86% | 2.5TCr | |
-3.29% | 2.45TCr |